Crystalline form of N-[[4-fluoro-2- (5-methyl-1H-1,2,4-triazol-1-yl) phenyl]methyl]-4,6,7,9-tetrahydro-3hydroxy-9,9-dimethyl-4-oxo-pyrimido [2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate

Details for Australian Patent Application No. 2009228254 (hide)

Owner BRISTOL-MYERS SQUIBB COMPANY

Inventors Ng, Alicia Tee Fuay; Choi, Candice Y.

Agent A J Park

Pub. Number AU-A-2009228254

PCT Pub. Number WO2009/120841

Priority 61/039,989 27.03.08 US

Filing date 26 March 2009

Wipo publication date 1 October 2009

International Classifications

C07D 498/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 31/18 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

23 September 2010 PCT application entered the National Phase

  PCT publication WO2009/120841 Priority application(s): WO2009/120841

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009228256-Method and apparatus for resource allocation in wireless communication systems

2009228250-Leucine-rich peptide compositions and methods for isolation